Implementation of a Health Action Process Approach-Based Program for People on Hemodialysis Treatment

December 9, 2024 updated by: Yelda KOÇAK, TC Erciyes University

The Effect of Health Action Process Approach-Based Program on Hemodialysis Patients' Adherence to Treatment and Quality of Life

The aim of the study is to determine the effect of the Health Action Process Approach (HAPA) based program on the treatment compliance and quality of life of people undergoing hemodialysis treatment. The hypotheses of the study are as follows:

  • The Health Action Process Approach Based Program has an effect on the treatment compliance of people undergoing hemodialysis treatment.
  • The Health Action Process Approach Based Program has an effect on the quality of life of people undergoing hemodialysis treatment.
  • The Health Action Process Approach Based Program has an impact on the results of laboratory tests and clinical parameters of people receiving hemodialysis treatment.

The population of the study will consist of people receiving hemodialysis treatment in the main service building and additional service building of Kahramanmaraş Necip Fazıl City Hospital. Patients who meet the criteria of ''volunteering to participate in the study, being over the age of 18, being literate, not having any problems that may prevent communication, not having a history of neurological or psychiatric disease, being on hemodialysis treatment for at least six months, and the vascular access used for hemodialysis being effective'' will be included in the study. Written informed consent will be obtained from patients who volunteer to participate in the study. At least 32 people who meet the inclusion criteria will be included in each group. The intervention group will receive a program based on the Health Action Process Approach (HAPA). No program will be applied to the control group.

The data collection tools of the study consist of the Participant Information Form, Participant Evaluation Form Based on the Health Action Process Approach, End-Stage Renal Disease Adherence Scale (ESRD-AQ), Fluid Control Scale in Hemodialysis Patients, Diet Information Scale of Hemodialysis Patients, Diet Behavior Scale of Hemodialysis Patients, Quality of Life (SF-36) Form, Laboratory Tests Follow-up Form and Homework Form. Measurements of the groups will be taken at the beginning of the study, week 6 (at the end of the program), month 3 and month 6.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The Health Action Process Approach (HAPA) Model was developed by Ralf Schwarzer in 1992 to understand the process of health behavior change. The Health Action Process Approach Model focuses on the "intention-behavior gap", which states that intentions to perform the behavior are sometimes not sufficient to take action to perform the behavior. Other social cognitive models are criticized for this "intention-behavior gap". Because in most of these models, it is stated that intention is the most important predictor for behavior change, and if the intention to perform the behavior is formed, the behavior will occur; however, intentions do not always turn into behavior. In order to close the intention-behavior gap, the HAPA Model proposes to evaluate the pre-intention motivation processes that lead to behavioral intention and the post-intention volitional processes that lead to behavior in two separate stages. The motivation stage of the model includes the components of "risk perception", "outcome expectations" and "action self-efficacy" and it is thought that the formation of behavioral intention depends on these components. The volitional stage of the model includes "action planning", "coping planning", "coping self-efficacy", "improvement self-efficacy" and "social support" and these are effective in the realization and maintenance of health behaviors. The HAPA Model is an important model in terms of providing a detailed and comprehensive description of the motivation processes before the formation of health behavior intention, the transformation of intention into behavior and the maintenance of behavior within these components. The volitional stage of the model includes "action planning", "coping planning", "coping self-efficacy", "improvement self-efficacy" and "social support" and these are effective in the realization and maintenance of health behaviors. The HAPA Model is an important model in terms of providing a detailed and comprehensive description of the motivation processes before the formation of health behavior intention, the transformation of intention into behavior and the maintenance of behavior within these components.

Health Action Process Approach-Based Program: The program is planned for six weeks (six sessions). Sessions will be held once a week for 30-45 minutes. Within the scope of the program, care - structured nursing care plans based on the Health Action Process Approach will be made -, education and counseling will be provided. Sessions will be held in a quiet, calm environment in the hospital, and if such an environment cannot be provided, they will be held at the patient's home. The day, time and place of the sessions will be decided together with the participant after each interview or session. At the beginning of each session, the previous session will be briefly recalled and the homework (SWOT analysis, treatment adherence tracking chart or SMART goal plan) given in the previous session will be evaluated. At the end of each session, the evaluation of that day's session will be carried out briefly.

In the study, two groups will be formed as intervention and control groups. No program will be applied to the intervention group. Routine treatment and care will continue. The control group will receive routine treatment and care as well as a program based on the Health Action Process Approach. Hemodialysis Treatment Adherence Handbook will be given to the intervention group when the study is completed. Participants in both groups will fill out the Health Action Process Approach-Based Participant Evaluation Form, Laboratory Tests Monitoring Form, End Stage Renal Failure Compliance Scale, Fluid Control Scale in Hemodialysis Patients, Dietary Knowledge Scale of Hemodialysis Patients, Dietary Behavior Scale of Hemodialysis Patients and Quality of Life (SF-36) Form. These forms will be completed at the beginning of the study (week 0), week 6 (at the end of the program), month 3 and month 6.

Study Type

Interventional

Enrollment (Estimated)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Kahramanmaraş, Turkey
        • Recruiting
        • Kahramanmaraş Necip Fazıl City Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Volunteering to participate in the study
  • Over 18 years of age
  • Being literate
  • Not having any problems with speech, hearing or vision that may interfere with communication
  • No history of neurological or psychiatric disease
  • Being on hemodialysis treatment for at least six months
  • The vascular access (catheter, fistula or graft) used to administer hemodialysis is working effectively

Exclusion Criteria:

  • Not meeting the inclusion criteria
  • Participation in a program based on the Health Action Process Approach related to the subject

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control Group
No program will be applied to the control group. Routine treatment and care in the hospital will continue. At the end of the study, a Handbook for Adherence to Hemodialysis Treatment will be given.
Experimental: Intervention Group
Program based on the Health Action Process Approach will be implemented. Hemodialysis Treatment Compliance Handbook will be given.
Other: Health Action Process Approach-Based Program
Health Action Process Approach-Based Program: The program is planned for six weeks (six sessions). Sessions will be held once a week for 30-45 minutes. Within the scope of the program, care - structured nursing care plans based on the Health Action Process Approach will be made -, education and counseling will be provided. Sessions will be held in a quiet, calm environment in the hospital, and if such an environment cannot be provided, they will be held at the patient's home. The day, time and place of the sessions will be decided together with the participant after each interview or session. At the beginning of each session, the previous session will be briefly recalled and the homework (SWOT analysis, treatment adherence tracking chart or SMART goal plan) given in the previous session will be evaluated. At the end of each session, the evaluation of that day's session will be carried out briefly.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in URR value of people on haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in haemoglobin value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in potassium value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in sodium value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in creatinine value of people on haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in Kt/V value of people receiving haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in urea value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in calcium value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in phosphorus value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Taken from patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in glucose value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in total protein value of people on haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in MCH value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Changes in ALT values of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in RBC value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Changes in AST values of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in albumin value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Changes in WBC values of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in MCV value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in PLT value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in haematocrit value of people undergoing haemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
It will be taken from the patient file.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in blood pressure of a person undergoing hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Blood pressure value at the entrance and exit of hemodialysis will be measured.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in the pulse rate of a person receiving hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
The person's pulse rate will be measured at the entrance and exit of hemodialysis treatment.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in respiratory rate of a person receiving hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
The respiratory rate of the person will be measured at the entrance and exit of hemodialysis treatment.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in oxygen saturation of a person receiving hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Oxygen saturation will be measured at the entrance and exit of hemodialysis treatment.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in body temperature of the person receiving hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Body temperature will be measured at the entrance and exit of hemodialysis treatment.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in weight at entry and exit of hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Hemodialysis treatment entry and exit weight will be weighed.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Changes in dry weight of a person undergoing hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
The dry weight of the person receiving hemodialysis treatment will be weighed.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Interdialytic weight changes in a person receiving hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
The interdialytic weight of the person receiving hemodialysis treatment will be weighed.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Changes in the attendance of people receiving hemodialysis treatment at hemodialysis sessions
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Health Action Process Approach Based Participant Evaluation Form: It is a form created by the researcher based on the studies in the literature. There are 11 questions regarding participation in hemodialysis sessions. The questions can be answered "yes", "partially" and "no".
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Changes in adherence to dietary restriction in people receiving hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Health Action Process Approach Based Participant Evaluation Form: It is a form created by the researcher based on the studies in the literature. There are 11 questions regarding the compliance of people receiving hemodialysis treatment with dietary restriction. The questions can be answered "yes", "partially" and "no".
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Changes in compliance with fluid restriction in people on hemodialysis
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Health Action Process Approach Based Participant Evaluation Form: It is a form created by the researcher based on the studies in the literature. There are 11 questions regarding the compliance of people receiving hemodialysis treatment with fluid restriction. The questions can be answered "yes", "partially" and "no".
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Changes in adherence to medication use among people receiving hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Health Action Process Approach Based Participant Evaluation Form: It is a form created by the researcher based on the studies in the literature. There are 11 questions regarding the medication compliance of people receiving hemodialysis treatment. The questions can be answered "yes", "partially" and "no".
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in adherence of people on hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ): The scale consists of four sections: participation in haemodialysis treatment, medication use, fluid restriction and dietary restriction. A score between 0-1200 can be obtained from the scale. The increase in the score obtained from the scale indicates an increase in treatment compliance. There are no reverse coded items in the scale. Since the items in the scale do not have a homogenous structure, Cronbach's alpha coefficient cannot be calculated.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in treatment adherence (dietary adherence) of people receiving hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Dietary Knowledge Scale of Hemodialysis Patients: It was used to evaluate the dietary compliance of people undergoing haemodialysis treatment in detail. The scale has a 3-point Likert type. The questions can be answered as ''true'', ''false'' and ''don't know''. The answers are scored as 1, 0 and 0 respectively. There are no reverse coded items. Scores between 0-18 can be obtained from the scale. The increase in the score indicates that the level of knowledge is good. Cronbach Alpha value is 0.86.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in treatment adherence (dietary adherence) of people receiving hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Dietary Behaviour Scale of Hemodialysis Patients: It was used to evaluate the dietary compliance of people undergoing haemodialysis treatment in detail. The scale consists of one sub-dimension and 13 items. The items are scored as ''strongly disagree=1, disagree= 2, undecided= 3, agree= 4, strongly agree= 5''. There are no items that need to be reverse coded. A score between 13-65 can be obtained from the scale. A high score indicates that the behavioural status is 'good'.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in adherence to treatment (adherence to fluid restriction) of people receiving hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Fluid Control Scale in Haemodialysis Patients: It was used to evaluate in detail the compliance of people on haemodialysis treatment with fluid restriction. The scale consists of 24 items and three sub-dimensions (knowledge-behaviour-attitude). The items are scored as ''agree=3, undecided=2, disagree=1''. Items 6, 7, 18, 19, 20, 21, 22, 23, 24 are scored by reverse coding. A score between 24-72 can be obtained from the scale. The increase in the score obtained from the scale indicates that the fluid control of the patients also increases.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Change in the quality of life of people undergoing hemodialysis treatment
Time Frame: Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month
Quality of Life (SF-36) Form: It was used to assess the quality of life of people undergoing haemodialysis treatment. The scale consists of eight sub-dimensions (physical function, social function, pain, vitality (energy), role limitation-emotional, role limitation-physical, mental health, general perception of health) and 36 items. The total score of the scale is not calculated and the total scores of the sub-dimensions are calculated separately. The scores that can be obtained vary between 0-100. A high score indicates a high quality of life.
Beginning of the study (week 0), week 6 (at the end of the program), 3rd month, and 6th month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

TC Erciyes University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 23, 2024

Primary Completion (Estimated)

January 1, 2025

Study Completion (Estimated)

January 1, 2026

Study Registration Dates

First Submitted

December 4, 2024

First Submitted That Met QC Criteria

December 4, 2024

First Posted (Actual)

December 9, 2024

Study Record Updates

Last Update Posted (Estimated)

December 12, 2024

Last Update Submitted That Met QC Criteria

December 9, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • YKOCAK

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hemodialytic Patients

Clinical Trials on Health Action Process Approach-Based Program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe